159 related articles for article (PubMed ID: 31264078)
21. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
[TBL] [Abstract][Full Text] [Related]
22. Automated time-resolved immunofluorometric assay for progastrin-releasing peptide.
Nordlund MS; Warren DJ; Nustad K; Bjerner J; Paus E
Clin Chem; 2008 May; 54(5):919-22. PubMed ID: 18443179
[TBL] [Abstract][Full Text] [Related]
23. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
24. Exploring the application value of pro-gastrin-releasing peptide in the clinical diagnosis and surgical treatment of medullary thyroid carcinoma.
Miao Q; Lv X; Luo L; Zhang J; Cai B
Cancer Med; 2023 Oct; 12(19):19576-19582. PubMed ID: 37754747
[TBL] [Abstract][Full Text] [Related]
25. IL-6 and VEGF in small cell lung cancer patients.
Wójcik E; Jakubowicz J; Skotnicki P; Sas-Korczyńska B; Kulpa JK
Anticancer Res; 2010 May; 30(5):1773-8. PubMed ID: 20592377
[TBL] [Abstract][Full Text] [Related]
26. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure.
Nomura F; Koyama A; Ishijima M; Takano S; Narita M; Nakai T
Oncol Rep; 1998; 5(2):389-92. PubMed ID: 9468564
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of pro-gastrin releasing peptide promotes the cell proliferation and progression in small cell lung cancer.
Gong Z; Lu R; Xie S; Jiang M; Liu K; Xiao R; Shen J; Wang Y; Guo L
Biochem Biophys Res Commun; 2016 Oct; 479(2):312-318. PubMed ID: 27639644
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis].
WANG J; GAO J; HE J
Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1094-100. PubMed ID: 21159242
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer.
Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N
Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547
[TBL] [Abstract][Full Text] [Related]
31. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S
Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241
[TBL] [Abstract][Full Text] [Related]
32. Serum neuron-specific enolase (NSE) as a tumour marker for the Ewing's sarcoma family of tumours.
Fizazi K; Le Cesne A; Dohollou N; Affaied S; Spielmann M; Le Chevalier T
Eur J Cancer; 1996 Sep; 32A(10):1823-4. PubMed ID: 8983301
[No Abstract] [Full Text] [Related]
33. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer.
Li L; Zhang Q; Wang Y; Xu C
J Clin Lab Anal; 2023 Apr; 37(7):e24865. PubMed ID: 37088873
[TBL] [Abstract][Full Text] [Related]
34. The influence of different blood samples treatment methods on pro-gastrin-releasing peptide.
Jiang H; Luo L; Xiong K; He C; Wang H; Qin Y
Medicine (Baltimore); 2019 Jun; 98(26):e16130. PubMed ID: 31261534
[TBL] [Abstract][Full Text] [Related]
35. Pro-Gastrin Releasing Peptide: A New Serum Marker for Endometrioid Adenocarcinoma.
Kiseli M; Caglar GS; Yarci Gursoy A; Tasci T; Candar T; Akincioglu E; Pabuccu EG; Boran N; Tulunay G; Umudum H
Gynecol Obstet Invest; 2018; 83(6):540-545. PubMed ID: 29898448
[TBL] [Abstract][Full Text] [Related]
36. An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival.
Korse CM; Taal BG; Bonfrer JMG; Vincent A; van Velthuysen ML; Baas P
Ann Oncol; 2011 Dec; 22(12):2625-2630. PubMed ID: 21415235
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of progastrin-releasing peptide, neuron-specific enolase, chromogranin a, and squamous cell cancer antigen in pulmonary neuroendocrine tumors.
Tutar N; Yetkin NA; Yazıcı C; Önal Ö; Kontaş O; Keleştemur F
Turk J Med Sci; 2019 Jun; 49(3):774-781. PubMed ID: 31091854
[TBL] [Abstract][Full Text] [Related]
38. Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.
Ueland T; Gullestad L; Kou L; Aukrust P; Anand IS; Broughton MN; McMurray JJ; van Veldhuisen DJ; Warren DJ; Bolstad N
ESC Heart Fail; 2018 Dec; 5(6):1052-1059. PubMed ID: 30145817
[TBL] [Abstract][Full Text] [Related]
39. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen.
Niho S; Nishiwaki Y; Goto K; Ohmatsu H; Matsumoto T; Hojo F; Ohe Y; Kakinuma R; Kodama T
Lung Cancer; 2000 Mar; 27(3):159-67. PubMed ID: 10699689
[TBL] [Abstract][Full Text] [Related]
40. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]